JP2022525400A5 - - Google Patents
Info
- Publication number
- JP2022525400A5 JP2022525400A5 JP2021555170A JP2021555170A JP2022525400A5 JP 2022525400 A5 JP2022525400 A5 JP 2022525400A5 JP 2021555170 A JP2021555170 A JP 2021555170A JP 2021555170 A JP2021555170 A JP 2021555170A JP 2022525400 A5 JP2022525400 A5 JP 2022525400A5
- Authority
- JP
- Japan
- Prior art keywords
- target portion
- unbound target
- salt
- unbound
- bound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962818030P | 2019-03-13 | 2019-03-13 | |
| US62/818,030 | 2019-03-13 | ||
| PCT/US2020/022130 WO2020185917A1 (en) | 2019-03-13 | 2020-03-11 | Sodium fluorescein as a reversal agent for an anti-fluorescein car t cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525400A JP2022525400A (ja) | 2022-05-13 |
| JP2022525400A5 true JP2022525400A5 (https=) | 2023-03-14 |
Family
ID=72426940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555170A Pending JP2022525400A (ja) | 2019-03-13 | 2020-03-11 | フルオレセインエーテルリン脂質またはフルオレセインエーテルリン脂質前駆体と併用した抗フルオレセインｃａｒ ｔ細胞に対する拮抗薬としてのフルオレセインナトリウム |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220125841A1 (https=) |
| EP (1) | EP3937975A4 (https=) |
| JP (1) | JP2022525400A (https=) |
| AU (1) | AU2020237097A1 (https=) |
| CA (1) | CA3140210A1 (https=) |
| WO (1) | WO2020185917A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12312416B2 (en) * | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| EP4228660A4 (en) * | 2020-10-14 | 2025-02-26 | Georgia Tech Research Corporation | Synthetic antigens as chimeric antigen receptor (car) ligands and uses thereof |
| WO2023224715A1 (en) * | 2022-05-19 | 2023-11-23 | Massachusetts Institute Of Technology | Car cells targeting an inserted ligand |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) * | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| CA2968145C (en) * | 2014-11-17 | 2023-06-27 | Cellectar Biosciences, Inc. | Phospholipid ether analogs as cancer-targeting drug vehicles |
| AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| US11408005B2 (en) * | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| US11649288B2 (en) * | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) * | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
-
2020
- 2020-03-11 WO PCT/US2020/022130 patent/WO2020185917A1/en not_active Ceased
- 2020-03-11 AU AU2020237097A patent/AU2020237097A1/en not_active Abandoned
- 2020-03-11 JP JP2021555170A patent/JP2022525400A/ja active Pending
- 2020-03-11 EP EP20770256.4A patent/EP3937975A4/en active Pending
- 2020-03-11 CA CA3140210A patent/CA3140210A1/en active Pending
- 2020-03-11 US US17/438,231 patent/US20220125841A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022525400A5 (https=) | ||
| Rohaan et al. | Adoptive cellular therapies: the current landscape | |
| JP6757959B2 (ja) | 抗がん剤 | |
| AU2019218729B2 (en) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors | |
| ES2765949T3 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| JP2021523110A (ja) | 遺伝子発現のためのナノ粒子及びその使用 | |
| JP2023504286A5 (https=) | ||
| US20200181264A1 (en) | Bispecific antigen-binding molecule | |
| CA3101340A1 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof | |
| JP2010110329A5 (https=) | ||
| JP2021502330A (ja) | Ｔｉｇｉｔおよび／またはｃｄ１１２ｒを標的とするか、またはｃｄ２２６過剰発現を含む、組成物および免疫治療の方法 | |
| JP2023030005A (ja) | 養子細胞治療を改善するための方法 | |
| JP2020533289A5 (https=) | ||
| JP2021509678A (ja) | Ｃｃｒ２アンタゴニストによる固形腫瘍の治療方法 | |
| JP2023500293A (ja) | 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途 | |
| WO2017026502A1 (ja) | 抗ポドプラニン抗体及び抗体薬物複合体 | |
| EP4185326A1 (en) | Compositions and methods for treating cancer | |
| US20260091123A1 (en) | Combination of anti-b7-h3 antibody-drug conjugate and atr inhibitor or atm inhibitor | |
| Feng et al. | Nanobody-directed CEA-targeting CAR T cells eliminate gastrointestinal cancer xenografts | |
| EP2976360A1 (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| CN113316449A (zh) | 胍那苄作为免疫疗法的佐剂 | |
| US20190211109A1 (en) | Chronic car treatment for cancer | |
| WO2023091905A1 (en) | Targeted extracellular vesicles and methods of use thereof | |
| KR102562878B1 (ko) | 질환 항원이 융합된 단백질 및 이의 용도 | |
| WO2023044039A1 (en) | Compositions and methods for treating cancer |